Browsing Tag
Exparel
4 posts
Viatris launches $1.65bn Pacira tender, but 11-cent share-price gap limits potential upside
Viatris has formally launched its $36.50-per-share tender offer for Pacira BioSciences, advancing a $1.65 billion acquisition intended to strengthen its non-opioid pain management business. Newly disclosed negotiations show the offer increased from $31 per share, while the buyer's projected savings, Pacira's patent exposure and a November 16 tender deadline shape the remaining investment considerations.
How the NOPAIN Act could support broader reimbursement momentum for EXPAREL
Could the NOPAIN Act accelerate EXPAREL adoption in outpatient orthopedic surgery? Explore the reimbursement and opioid-reduction implications.
How opioid reduction strategies are driving cost savings in orthopedic surgery pathways
Find out how Pacira BioSciences, Inc. is using EXPAREL data to drive opioid reduction and cost savings in Medicare orthopedic surgery pathways.
Can ATX101 disrupt the multibillion-dollar post-surgical pain market?
Can Allay Therapeutics’ ATX101 replace opioids in post-surgical care? Read how this long-acting bupivacaine platform may disrupt the pain relief market by 2026.